Controlled Human Malaria Infection Transmission Model - Phase A

PHASE1/PHASE2SuspendedINTERVENTIONAL
Enrollment

44

Participants

Timeline

Start Date

August 22, 2022

Primary Completion Date

December 31, 2025

Study Completion Date

August 31, 2026

Conditions
Malaria,Falciparum
Interventions
BIOLOGICAL

PfSPZ Challenge

Aseptic, purified, cryopreserved Plasmodium falciparum sporozoites

DRUG

Sulfadoxine-Pyrimethamine

Sub-curative 500mg/25mg single dose regimen

DRUG

Piperaquine

Sub-curative 480mg single dose regimen

DRUG

Artemether lumefantrine

Three day curative regimen 20mg/120mg

DRUG

Primaquine

Single low dose regimen 0.25 mg base/kg

Trial Locations (1)

80108

KEMRI-Wellcome Trust Research Programme, Kilifi

Sponsors
All Listed Sponsors
collaborator

KEMRI-Wellcome Trust Collaborative Research Program

OTHER

collaborator

Sanaria Inc.

INDUSTRY

collaborator

Kenya Medical Research Institute

OTHER

lead

University of Oxford

OTHER